Table 1 Commonly recommended drug therapies by income setting
From: Variation in hypertension clinical practice guidelines: a global comparison
Income setting | First-step therapy | Second-step therapy | Third-step therapy |
|---|---|---|---|
All (n = 48) | Any one of: • ACEi/ARB • CCB • Diuretic (33% of CPGs) | ACEi + CCB/diuretic (19% of CPGs) | ACEi/ARB + CCB + Diuretic (59% of CPGs) |
Low-income countries (n = 8) | Diuretic (63% of CPGs) | No distinct majority (6 different combinations) | ACEi/ARB + CCB + Diuretic (60% of CPGs) |
Lower-middle income countries (n = 10) | CCB/diuretic (30% of CPGs) | CCB/diuretic + ACEi/ARB (30% of CPGs) | ACEi/ARB + CCB + Diuretic (83% of CPGs) |
Upper-middle income countries (n = 11) | Any one of: • ACEi/ARB • CCB • Diuretic • Beta-blocker (45% of CPGs) | No distinct majority (7 different combinations) | ACEi/ARB + CCB + Diuretic (50% of CPGs) |
High-income countries (n = 18*) *Including ISH 2020 optimal | Any one of: • ACEi/ARB • CCB • Diuretic (47% of CPGs) | No distinct majority (8 different combinations) | ACEi/ARB + CCB + Diuretic (50% of CPGs) |